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two scenarios defined by different tissue parameter values 
(α/β)x representing high and low radio-sensitivity. We 
systematically compared RBE predictions as a function of 
(α/β)x and proton linear energy transfer (LET) values in a 
spread-out Bragg peak (SOBP) in water and analysed results 
on patient-CT anatomy for cranial irradiation in terms of 
absorbed dose-to-water, dose-averaged LET (LETD), RBE-
weighted dose-to-water and biological range shift 
distributions.  
Results: Different levels of agreement depending on (α/β)x 
and LET values were found in the systematic comparison of 
RBE predictions. The SOBP study emphasizes a variation of 
LETD and RBE not only as a function of depth but also of 
lateral distance from the central beam axis. Applying the 
different models to cranial treatment plans we observe 
consistent discrepancies from the values obtained for a 
constant RBE of 1.1 when using the variable RBE scheme in 
tissues with low (α/β)x, regardless of the model. An example 
is reported in figure 1. Biological range shifts of (0.6-2.4) mm 
(high (α/β)x) and (3.0-5.4) mm (low (α/β)x) were found in the 
fall-off analysis of individual profiles of RBE-weighted 
fraction dose along the beam penetration depth. 
Conclusions: Although more experimental evidence is 
required to validate the accuracy of the investigated models, 
their consistent trend suggests that their main RBE 
dependencies should be included in treatment planning 
systems. Evaluation of the impact of a variable RBE scheme 
on the plan optimized using a constant RBE would thus be 
enabled, constituting a first step towards a more robust 
choice of biological dose delivery in proton therapy. 
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Biological dose calculated using the constant factor of 1.1 
(left) or two different radio-biological models [2,3,5] for low 
(α/β)x, overlaid on the treatment planning CT image; Contour 
outlines the physical target volume.  
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Radiotherapy has proven efficacy to inactivate cancer stem 
cells and is a highly personalized treatment modality, 
tailoring treatment plans for each individual patient based on 
precise anatomical information on tumor size and location as 
well as on normal tissues in the irradiated volume. Models 
based on clinical data, radiobiology and radiation physics are 
routinely used in radiotherapy for generating individualized 
space-resoluted radiation dose distributions, as well as for 
assessment of tumor control probability- vs. normal tissue 
complication-models. Tremendous improvement in high-
precision radiation delivery and planning technology has been 
achieved during the past decades and rapidly been translated 
into clinical practice. 
The new frontier in radiation oncology-related research is 
now to bring together advances in tumor and molecular 
biology with the full potential of high-precision radiation 
technology. Examples of these developments include the 
discovery and assessment of biomarkers specific for 
radiotherapy, the combination of radiotherapy with 
molecular targeted drugs, and the individualization of 
treatment planning by biological imaging. Individualized 
radiotherapy in the future will integrate biological 
information on the specific tumor and on surrounding normal 
tissues in the treatment strategy of patients. Novel 
predictive and prognostic markers demonstrate high potential 
for advancing personalized radiation oncology in preclinical 
and clinical-translational studies. So far this applies for 
stratified selection of total dose, however, in the future also 
personalized dose-distribution and fractionation parameters 
as well for the combined therapies of radiation with specific 
drugs might become predictable by biomarkers. A specific 
feature of personalized radiation oncology is that already 
broad biological stratification of patients has the potential to 
remarkable advance individualization of therapy as this 
information adds a power-function to the fully anatomically-
personalized dose-distributions clinically achieved today. 
This talk will review preclinical and clinical examples of 
potential strategies to increase cure rates by adding a biology 
dimension (e.g. predictive/ prognostic markers) to 
personalized radiation oncology. 
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Purpose:  Several studies indicate the potential dosimetric 
benefit of combining IMRT and VMAT in a hybrid approach [1, 
2].  This study evaluates the accuracy of in-vivo portal 
dosimetry for a variety of hybrid IMRT and VMAT plans for 
radiotherapy of the prostate. 
Materials/methods:  Hybrid IMRT and VMAT plans were 
retrospectively constructed for five prostate patients.  Three 
PTVs were used, namely PTV74Gy, PTV71Gy and PTV60Gy.  
For each patient, seven 6MV plans were created: a conformal 
VMAT arc, a VMAT arc with limited modulation, and five 
hybrid IMRT / VMAT arcs, with 0%, 25%, 50%, 75% and 100% 
IMRT respectively, with 0% corresponding to normal VMAT 
and 100% corresponding to 11-beam IMRT.  All plans consisted 
of a single anticlockwise arc with 111 segments ranging in 
gantry angle from 110° to 250°.  The hybrid plans were 
created by grouping the control points into 20° groups, and 
then selecting the groups with the most complex intensity 
maps for sequencing as IMRT, with the remaining groups 
sequenced for VMAT. 
Predicted integrated portal images were created for all plans 
as delivered to a water-equivalent phantom [3].  The plans 
were then delivered to the phantom as a single beam 
sequence using an Elekta Synergy accelerator with Agility 
head and integrated images were measured using an Elekta 
iViewGT portal imager.  Predicted and measured images 
were compared in terms of mean gamma and percentage 
